SEVEN FLEET CAPITAL MANAGEMENT LP
Q3 2026 Form 13-F
MOUNTAIN VIEW, DELAWARE
CIK 0002092021
· CRD 335203
· SEC-registered investment adviser
Consolidated report · includes
1 manager
since Q4 2025
$511.7M Reported Value Total
SEVEN FLEET CAPITAL MANAGEMENT LP reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $434,581,362, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
2 funds
· $434.6M gross asset value
Hedge Fund: $263.1M · Other: $171.4M
Source: Form ADV filed 2026-11-11
Reported value
$511.7M
Quarter over quarter
-10.4%
Holdings
85
Top-10 concentration
68.9%
Filing Structure
Reports holdings for
- DV Trading LLC · File #028-26555 · since Q4 2025 · declared by one filing
Key People
Form ADV owners & control persons
Brian Guan-Chyun Liu
MANAGING MEMBER
Rod Seung-Hwan Lim
LIMITED PARTNER OF SEVEN FLEET MANAGEMENT LP
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 16, 2026 |
| Form | 13F-HR |
| Reported value | $511.7M |
| Positions | 85 |
| Change in reported value | -15.5% |
| New positions | 20 |
| Exited positions | 31 |
| Position turnover | 44.0% |
| Top-10 concentration | 68.9% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
85 | $511.7M |
|
Q2 2026 13F
Filed Aug 15, 2026
|
96 | $605.9M |
|
Q1 2026 13F
Filed May 15, 2026
|
115 | $318.3M |
|
Q4 2025 13F
Filed Feb 26, 2026
|
85 | $147.8M |
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | CGON CG ONCOLOGY INC | $133.7M | 26.13% |
| 2 | TNGX TANGO THERAPEUTICS INC | $55.7M | 10.89% |
| 3 | RVMD REVOLUTION MEDICINES INC | $54.3M | 10.61% |
| 4 | PHVS PHARVARIS N V | $22.2M | 4.34% |
| 5 | ENTX ENTERA BIO LTD | $20.0M | 3.9% |
| 6 | LQDA LIQUIDIA CORPORATION | $18.0M | 3.53% |
| 7 | AVBP ARRIVENT BIOPHARMA INC | $13.7M | 2.67% |
| 8 | ELVN ENLIVEN THERAPEUTICS INC | $12.0M | 2.35% |
| 9 | AVTX AVALO THERAPEUTICS INC | $11.8M | 2.31% |
| 10 | XNCR XENCOR INC | $11.1M | 2.17% |
| 11 | ROIV ROIVANT SCIENCES LTD | $10.6M | 2.07% |
| 12 | ABVX ABIVAX SA | $9.8M | 1.92% |
| 13 | ASMB ASSEMBLY BIOSCIENCES INC | $9.8M | 1.92% |
| 14 | MANE VERADERMICS INC | $9.7M | 1.9% |
| 15 | PTGX PROTAGONIST THERAPEUTICS INC | $6.4M | 1.26% |
| 16 | DMRA DAMORA THERAPEUTICS INC | $6.1M | 1.2% |
| 17 | IPSC CENTURY THERAPEUTICS INC | $6.1M | 1.19% |
| 18 | EPRX EUPRAXIA PHARMACEUTICALS INC | $5.2M | 1.02% |
| 19 | AXSM AXSOME THERAPEUTICS INC. | $4.4M | 0.87% |
| 20 | SGMT SAGIMET BIOSCIENCES INC | $4.2M | 0.83% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.